Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate02 saruparib adjuvant trial in BRCA-mutated high-risk localized/locally advanced prostate cancer
MOH_2026-01-20_015612Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of saruparib in prostate cancer (PCa) (4 cohorts), sponsored by AstraZeneca. Primary endpoint: Metastasis-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2026-01-20_015612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-20_015612.